FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI-based breast cancer risk technology receives FDA breakthrough device designation

2.

Report provides global picture of wide inequalities in care for women's cancers

3.

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.

4.

Small Renal Mass Surveillance Does Not Affect Nephron-Sparing Surgery.

5.

The Kansas Cancer Center awarded two Indian American doctors professorships.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot